Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-26T14:24:29.454Z Has data issue: false hasContentIssue false

Assessing the economic challenges posed by orphan drugs: A response to McCabe et al.

Published online by Cambridge University Press:  19 June 2007

Extract

To the Editor:

In their comment on our study, McCabe et al. make several points, with which some we agree and some we do not. Here, we respond to the most pertinent issues, using the same twelve headings.

Type
LETTERS TO THE EDITOR
Copyright
© 2007 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Blundell R, Costa Dias M. 2000 Evaluation methods of non-experimental data. Fiscal Studies. 21: 427468.Google Scholar
Commission of the European Communities. Commission Staff Working Document on the experience acquired as a result of the application of Regulation No. 141/2000 on orphan medicinal products and account of the public health benefits obtained. 20.6.2006, SEC(2006) 832. Brussels: Commission of the European Communities.
European Parliament and the Council of the European Union. Regulation EC No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities.
George B, Harris A, Mitchell A. 2001: Cost-effectiveness analysis and the consistency of decision making. Evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 19: 11031109.Google Scholar
Ministere delegue a la recherché. 2004. French National Plan for Rare Diseases 2005-2008. Ensuring equity in the access to diagnosis, treatment and provision of care. 20 November Paris: Ministere delegue a la recherché.